Ocular Therapeutix™ Reports Fourth Quarter and Year End 2019 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
Ocular Therapeutix (OCUL) Misses Q4 EPS by 8c, Revenues Miss
March 12, 2020 4:39 PM EDTOcular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.53), $0.08 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $2.26 million versus the consensus estimate of $2.54 million.
Ocular Therapeutix has had an impressive final quarter of 2019 and strong start to 2020, said Antony Mattessich,... More



